Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pharma Mar SA ( (ES:PHM) ) has provided an announcement.
Pharma Mar SA has completed its share buy-back program ahead of schedule, acquiring a total of 91,111 shares, which represents 0.5% of its share capital, for over 7.5 million euros. The completion of this program will lead to the amortization of these shares through a share capital reduction, and the resumption of operations under a liquidity contract with JB Capital Markets from June 23, 2025.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA operates in the pharmaceutical industry, focusing on the development and commercialization of drugs derived from marine organisms. The company is known for its innovative cancer treatments and has a strong presence in the biotechnology sector.
Average Trading Volume: 66,353
Technical Sentiment Signal: Buy
Current Market Cap: €1.46B
See more data about PHM stock on TipRanks’ Stock Analysis page.